<DOC>
	<DOCNO>NCT00652665</DOCNO>
	<brief_summary>To compare single-dose Bioavailability Kali Aventis</brief_summary>
	<brief_title>Bioavailability Study Leflunomide Tablets Under Fasting Conditions</brief_title>
	<detailed_description>To compare relative Bioavailability leflunomide 20mg tablet ARAVA 20mg tablet healthy , adult subject fast condition</detailed_description>
	<mesh_term>Leflunomide</mesh_term>
	<criteria>All subject select study least 18 year age . Females must physically unable become pregnant . Males must vasectomize . Each subject shall give general physical examination within 28 day initiation study . Such examination include , limited , blood pressure , general observation , history . Each female subject give serum pregnancy test part pre study screen process At end study , subject exit evaluation consist interim history , global evaluation , clinical laboratory measurement Adequate blood urine sample obtain within 28 day begin first period end trial clinical laboratory measurement Clinical laboratory measurement include hematology , clinical chemistry , urine analysis , HIV screen , hepatitisB , C screen , drug abuse screen dose . Subjects history chronic alcohol consumption ( past 2 year ) , drug addiction , recent serious gastrointestinal , renal , hepatic cardiovascular disease , tuberculosis , epilepsy , asthma ( past 5 year ) , diabetes , psychosis glaucoma eligible study Subjects whose clinical laboratory test value great tahn 20 % outside normal range may retested.If clinical value side range retesting subject eligible participate study unless clinical investigator deem result significant Subjects history allergic response class drug test excluded study.Subjects history allergic response cholestyramine exclude study . All subject urine sample assay presence drug abuse part clinical laboratory screening procedure checkin dose . Subjects find urine concentration test drug allow participate . Subjects donate blood and/or plasma least thirty ( 30 ) day prior first dose study . Subjects take investigational drug within thirty ( 30 ) day prior first dose study allow participate . Female subject pregnant able ( woman child bear potential ) become pregnant study allow participate . All female subject screen pregnancy checkin . Subjects positive inconclusive result withdrawn study . Male subject physically able father child allow participate . Male subject must vasectomize ( least 3 month ) medical verification . Subjects take product contain leflunomide within 180 day dose allow participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Bioequivalence , single-dose , fast</keyword>
</DOC>